Patents by Inventor Rainer Oelze

Rainer Oelze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
    Patent number: 8114906
    Abstract: A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA/DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: February 14, 2012
    Assignee: Abbott Products GmbH
    Inventors: Cees-Nico Verboom, Rainer Oelze
  • Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
    Publication number: 20050245610
    Abstract: A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA/DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.
    Type: Application
    Filed: April 15, 2005
    Publication date: November 3, 2005
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Cees-Nico Verboom, Rainer Oelze
  • Treatment of diabetic patients with omega-3-fatty acids
    Publication number: 20040235948
    Abstract: The use of essential fatty acids with a high content of eicosapentaenoic acid ethyl ester (EPA) and/or docosahexaenoic acid ethyl ester (DHA) for preventing cardiovascular events in patients with diabetes mellitus.
    Type: Application
    Filed: March 5, 2004
    Publication date: November 25, 2004
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Rainer Oelze, Cees-Nico Verboom